IP Library Granted Patent US 9,352,027
Granted Patent B2
US 9,352,027 · App. 14/286,391 · Granted May 31, 2016

Albumin-free factor VIII formulations

Inventors: Marc Besman (Studio City, CA); Erik Bjornson (Studio City, CA); Feroz Jameel (Covina, CA); Ramesh Kashi (Walnut, CA); Michael Pikal (Mansfield Center, CT); Serguei Tchessalov (Ashford, CT); John Carpenter (Littleton, CO)
Assignees: Baxalta Incorporated; Baxalta GmbH; University of Connecticut
A61K38/37A61K9/0019A61K9/19A61K47/02A61K47/10A61K47/18A61K47/183A61K47/26A61K47/38Y10S514/834Y10S530/829
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,352,027
App. No.
14/286,391
Granted
May 31, 2016
Kind
B2
Abstract

A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent.

Claims (10)

1. A liquid Factor VIII composition formulated without adding albumin to said composition, said composition comprising the following formulation excipients in addition to Factor VIII: 25 mM tris(hydroxymethyl)aminomethane, 4.2 mM calcium chloride, 8% (w/v) mannitol, 225 mM sodium chloride, 0.2 mg/mL glutathione, and 0.025% (w/v) polysorbate 80.

2. The composition of claim 1 , further comprising 25 mM histidine.

3. The composition of claim 2 , further comprising 2% (w/v) trehalose.

4. The composition of claims 1 to 3 , wherein the pH is between 6 and 8.

5. A liquid Factor VIII composition without albumin, said composition comprising the following formulation excipients in addition to Factor VIII: 10 mM tris(hydroxymethyl)aminomethane, 1.7 mM calcium chloride, 0.08 mg/mL glutathione, and 0.01% (w/v) polysorbate 80.

6. The composition of claim 5 , further comprising 10 mM histidine.

7. The composition of claim 6 , further comprising 1% trehalose.

8. The composition of claim 7 , further comprising 4% (w/v) mannitol.

9. The composition of claim 8 , further comprising 100 mM sodium chloride.

10. The composition of any of claims 5 to 9 , wherein the pH is between 6 and 8.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2016
From: BAXTER INTERNATIONAL INC.
To: BAXALTA INCORPORATED; BAXALTA GMBH
Reel/Frame 038347/0243 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2014
From: BESMAN, MARC; BJORNSON, ERIK; JAMEEL, FEROZ; KASHI, RAMESH; CARPENTER, JOHN
To: BAXTER INTERNATIONAL INC.
Reel/Frame 032981/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2014
From: PIKAL, MICHAEL; TCHESSALOV, SERGUEI
To: UNIVERSITY OF CONNECTICUT
Reel/Frame 032981/0019 →
Continuity (9)
Continuation 13760900 · Feb 6, 2013
Continuation 13250789 · Sep 30, 2011
Continuation 11764770 · Jun 18, 2007
Continuation 11434634 · May 15, 2006
Division 10610723 · Jul 1, 2003
Continuation 09507011 · Feb 22, 2000
Continuation In Part 09452752 · Dec 1, 1999
Continuation In Part 09255279 · Feb 22, 1999
Related Publication 20150025010A1 · Jan 22, 2015